TORONTO, Aug. 17, 2021 /CNW/ – Diamond Therapeutics Inc. (“Diamond”), a drug development company focused on low-dose psychedelic therapies for use in the treatment of mental health, is pleased to announce that it has received a No Objection Letter from Health Canada, allowing Diamond to proceed with a human clinical trial to evaluate low doses of psilocybin in healthy volunteers. The trial is a…


Previous articleField Trip Health Ltd. Reports Fiscal First Quarter 2022 Financial Results
Next articlePT258 – Manesh Girn – Psychedelics and the Brain: Neuroplasticity and Creativity